Type IV Collagen Neo-Epitope Assay for Immunotherapy Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapy treatments with immune checkpoint inhibitors are not effective for all cancer patients, necessitating the development of non-invasive biomarkers to identify those likely to respond, as the tumor microenvironment composition affects T-cell migration and activation.
Innovation Solution
A competitive electro-chemiluminescence immunoassay (ECLIA) targeting a neo-epitope of protease-mediated type IV collagen degradation, specifically recognizing the N-terminus amino acid sequence MGNTGPTGAV (SEQ ID No. 1), is developed to assess the T-cell permissive tumor microenvironment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immune checkpoint inhibitor therapy is administered to all cancer patients, then more patients may benefit from treatment, but treatment effectiveness is reduced due to lack of patient selection
Solution Approach 1:
The patent applies preliminary action by developing and applying a biomarker assay (detecting C4M and PRO-C3 levels in blood samples) before administering immune checkpoint inhibitor therapy. This pre-treatment screening identifies patients with immune-inflamed tumor microenvironments who are most likely to respond to therapy, ensuring that treatment is initiated only in appropriate candidates. The assay measures collagen degradation products and extracellular matrix composition as predictive indicators, allowing clinicians to select patients before treatment begins.
Solution Approach 2:
The patent uses blood-based biomarkers (C4M and PRO-C3) as intermediaries to indirectly assess the tumor microenvironment and predict treatment response. Instead of directly analyzing complex tumor tissue characteristics, the assay measures soluble collagen fragments and extracellular matrix components in circulating blood, which serve as mediators reflecting the underlying tumor-immune interactions. This intermediary approach simplifies patient stratification while maintaining predictive accuracy.
2Measurement precision
If biomarker assays are developed to identify responsive patients, then treatment precision is improved, but diagnostic complexity and testing requirements increase
Solution Approach 1:
The patent extracts specific, measurable biomarkers (C4M and PRO-C3) from the complex biological system of the tumor microenvironment. Instead of attempting to analyze the entire complexity of immune cell interactions and extracellular matrix composition directly in tumor tissue, the assay extracts and measures specific collagen degradation products and extracellular matrix fragments that can be detected in circulating blood. This extraction approach simplifies the diagnostic process while maintaining predictive power.
Solution Approach 2:
The patent replaces complex mechanical/tissue-based diagnostic methods with a biochemical assay system. Instead of requiring invasive tumor biopsies, histological analysis, or complex imaging to assess tumor microenvironment characteristics, the invention uses a blood-based immunoassay that measures specific protein markers. This substitution of mechanical tissue analysis with biochemical marker detection simplifies the diagnostic workflow and reduces procedural complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The assay effectively identifies cancer patients likely to respond to immune checkpoint inhibitor treatment and predicts survival outcomes, particularly in metastatic melanoma and pancreatic ductal adenocarcinoma, by quantifying the peptide levels in serum.
Implementation Method 1
a monoclonal antibody that specifically recognises and binds to a peptide having the N-terminus amino acid sequence MGNTGPTGAV
Implementation Method 2
a competitive electro-chemiluminescence immunoassay (ECLIA)
Data Source
AI summary
An assay measuring protease mediated degradation of type IV collagen and its biomarker potential for identifying cancer patients with a T-cell permissive tumor microenvironment is described.